Pharsight

Opfolda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10208299 AMICUS THERAP US Highly potent acid alpha-glucosidase with enhanced carbohydrates
Sep, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278599 AMICUS THERAP US High concentration alpha-glucosidase compositions for the treatment of Pompe disease
Mar, 2033

(9 years from now)

US10512677 AMICUS THERAP US High concentration alpha-glucosidase compositions for the treatment of pompe disease
Mar, 2033

(9 years from now)

US10961522 AMICUS THERAP US Highly potent acid alpha-glucosidase with enhanced carbohydrates
Sep, 2035

(11 years from now)

US11753632 AMICUS THERAP US Highly potent acid alpha-glucosidase with enhanced carbohydrates
Sep, 2035

(11 years from now)

US11278601 AMICUS THERAP US Augmented acid alpha-glucosidase for the treatment of Pompe disease
Dec, 2036

(12 years from now)

US10857212 AMICUS THERAP US Augmented acid alpha-glucosidase for the treatment of Pompe disease
Aug, 2037

(13 years from now)

Opfolda is owned by Amicus Therap Us.

Opfolda contains Miglustat.

Opfolda has a total of 7 drug patents out of which 0 drug patents have expired.

Opfolda was authorised for market use on 28 September, 2023.

Opfolda is available in capsule;oral dosage forms.

Opfolda can be used as the treatment of pompe patients.

The generics of Opfolda are possible to be released after 12 August, 2037.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Sep 28, 2026

Drugs and Companies using MIGLUSTAT ingredient

Market Authorisation Date: 28 September, 2023

Treatment: The treatment of pompe patients

Dosage: CAPSULE;ORAL

More Information on Dosage

OPFOLDA family patents

Family Patents